Novartis Pharma
VC Fund
Tokyo, Japan
Novartis Pharma is a VC fund in Tokyo focused on Health Care and Biotechnology. Novartis Pharma is the Japanese subsidiary of Novartis Pharmaceuticals, a world-leading healthcare company based in Basel, Switzerland
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Novartis Pharma invests in
Stages Novartis Pharma invests in
Countries Novartis Pharma invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $16M–$35M
- Series C
- $23M–$35M
Investment Focus
Industry
- Health Care 5 (63%)
- Biotechnology 5 (63%)
- Therapeutics 3 (38%)
- Medical Device 2 (25%)
- Medical 1 (13%)
Stage
- Series B 2 (25%)
- Series C 2 (25%)
- Series A 1 (13%)
- Funding Round 1 (13%)
- Post-IPO Equity 1 (13%)
Country
- United States 5 (63%)
- Japan 1 (13%)
- Germany 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alberto M. Pedroncelli
GMA Sr Franchise Head
|
GMA Sr Franchise Head | Total investments: 0 | Find email | |
Vas Narasimhan
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Alto Neuroscience
|
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $35M / Series B / Oct 25, 2022 | |
H1.co
|
H1 is an AI-powered platform that helps identify and engage the right doctors for critical workflows across pharma, health plan, health system, and technology companies. At the core of the platform is H1’s Doctor Graph—a structured representation of physician identity, expertise, relationships, and behavioral signals, creating a powerful networkeffect as it is continuously enriched by participants across the healthcare ecosystem. Built on one of the world’s largest and most comprehensive global datasets of healthcare professionals, H1 combines deep healthcare data with agentic AI workflows to power critical workflows across drug development, medical and commercial engagement, care navigation, and provider data and network intelligence. Founded in 2017, the company is based in New York, United States. | $23M / Series C / Jun 09, 2022 | |
SomaLogic
|
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscantechnology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado. | $375M / Post-IPO Equity / Sep 01, 2021 | |
Dopavision
|
Dopavision is a therapeutic company developing a digital therapeutic for myopia. Myopia, or shortsightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision. Dopavision is developing a digital therapeuticfor myopia which can be seamlessly and invisibly integrated with the use of a smartphone. Myopia is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades. The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years. | $14.2M / Series A / Jul 14, 2021 | |
Vineti
|
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatmentof late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016. | $33M / Series C / Oct 13, 2020 | |
Koneksa Health
|
Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies (bio-sensors, activity trackers, mobile-based questionnaires, etc.) into their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets.Koneksacurrently supports academic and life sciences researchers, expands the universe of data that can be analyzed while also removing subjective characteristics from clinical endpoints. It was founded in 2015 and is based in New York, United States. | $16M / Series B / Sep 28, 2020 | |
|
Vineti
|
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatmentof late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016. | $35M / Series C / Feb 05, 2020 | |
Peptidream
|
PeptiDream is a biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hitcandidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics. | $41.3M / Nov 13, 2012 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Novartis Pharma invest in?
Novartis Pharma invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series B and Series C stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Novartis Pharma's check size?
Novartis Pharma typically joins rounds of $16M–$35M at Series B and $23M–$35M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Novartis Pharma participates in.
How do I contact Novartis Pharma?
Public channels for Novartis Pharma include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Novartis Pharma?
The team at Novartis Pharma includes Alberto M. Pedroncelli (GMA Sr Franchise Head) and Vas Narasimhan (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
